Search

Your search keyword '"Camdessanché, Jean Philippe"' showing total 412 results
Start Over Author "Camdessanché, Jean Philippe"
412 results on '"Camdessanché, Jean Philippe"'

1. Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome

Author

Coly, Martin, Adams, David, Attarian, Shahram, Bouhour, Françoise, Camdessanché, Jean-Philippe, Carey, Guillaume, Cauquil, Cécile, Chanson, Jean-Baptiste, Chrétien, Pascale, Créange, Alain, Delmont, Emilien, Fargeot, Guillaume, Frachet, Simon, Gendre, Thierry, Kuntzer, Thierry, Labeyrie, Céline, Maisonobe, Thierry, Michaud, Maud, Moulin, Maximilien, Nicolas, Guillaume, Noury, Jean-Baptiste, Péréon, Yann, Puma, Angela, Sole, Guilhem, Taithe, Frédéric, Tard, Céline, Théaudin, Marie, Timsit, Serge, Venditti, Laura, and Echaniz-Laguna, Andoni

Published
2024
Full Text
View/download PDF

2. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

Author

Rollot, Fabien, Couturier, Justine, Casey, Romain, Wiertlewski, Sandrine, Debouverie, Marc, Pelletier, Jean, De Sèze, Jérôme, Labauge, Pierre, Ruet, Aurélie, Thouvenot, Eric, Ciron, Jonathan, Berger, Eric, Gout, Olivier, Clavelou, Pierre, Stankoff, Bruno, Casez, Olivier, Bourre, Bertrand, Zephir, Hélène, Moreau, Thibault, Lebrun-Frenay, Christine, Maillart, Elisabeth, Edan, Gilles, Neau, Jean-Philippe, Montcuquet, Alexis, Cabre, Philippe, Camdessanché, Jean-Philippe, Defer, Gilles, Nasr, Haifa Ben, Maurousset, Aude, Hankiewicz, Karolina, Pottier, Corinne, Leray, Emmanuelle, Vukusic, Sandra, and Laplaud, David-Axel

Published
2022
Full Text
View/download PDF

3. Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database.

Author

Attarian, Shahram, Camdessanché, Jean‐Philippe, Echaniz‐Laguna, Andoni, Ciumas, Mariana, Blein, Cécile, Grenier, Benjamin, and Solé, Guilhem

Subjects
*NATIONAL health insurance, *MYASTHENIA gravis, *INTRAVENOUS immunoglobulins, *INTENSIVE care units, *DATABASES
Abstract

Background and purpose Methods Results Conclusions Few data are available on the course of myasthenia gravis (MG) regarding disease severity and stability over time in real‐world settings. This study used the French National Health Insurance Database (SNDS) to assess markers of disease severity in patients with MG longitudinally.All patients with MG‐related claims in the SNDS between 2013 and 2020 were identified. Patients were followed for up to 8 years after the first claim. Intensive care unit (ICU) stays, treatment with intravenous immunoglobulin (IVIg) or plasma exchange (PE), and death were documented throughout the follow‐up period. Standardized mortality rates were estimated, and mortality‐related variables were identified using a Cox model.In all, 14,459 individuals constituted the full study population, including 6354 incident patients. In the incident population, 2199 (34.6%) were admitted to ICUs at least once, principally during the first year after the index date (N = 1477; 23.3%). This proportion decreased progressively to reach 3.0% in the seventh year. A total of 2817 patients received IVIg and 432 PE, again principally in the first year. In the full study population, the standardized mortality rate was 1.08 (95% confidence interval [CI] 1.03–1.13), being lower in men (0.95, 95% CI 0.89–1.02) than in women (1.15, 95% CI 1.07–1.23) and in patients aged >65 years (1.06, 95% CI 1.01–1.11) than in younger patients (1.50, 95% CI 1.24–1.76). Male gender, older age and higher comorbidity were independently associated with mortality.A subgroup of patients with MG require ICU admission and rescue therapy with IVIg or PE, indicative of poor disease control. New therapies are needed to improve disease control and reduce disease burden. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study

Author

Levraut, Michael, Laurent-Chabalier, Sabine, Ayrignac, Xavier, Bigaut, Kévin, Rival, Manon, Squalli, Sanae, Zéphir, Hélène, Alberto, Tifanie, Pekar, Jean-David, Ciron, Jonathan, Biotti, Damien, Puissant-Lubrano, Bénédicte, Camdessanché, Jean-Philippe, Tholance, Yannick, Casez, Olivier, Toussaint, Bertrand, Marion, Jeanne, Moreau, Thibault, Lakomy, Daniela, Thomasset, Audrey, Maillart, Elisabeth, Sterlin, Delphine, Maurousset, Aude, Rocher, Auriane, Laplaud, David Axel, Bigot-Corbel, Edith, Bertho, Pierre-Olivier, Pelletier, Jean, Boucraut, Joseph, Labauge, Pierre, Vincent, Thierry, De Sèze, Jérôme, Jahn, Isabelle, Seitz-Polski, Barbara, Thouvenot, Eric, and Lebrun-Frenay, Christine

Published
2023
Full Text
View/download PDF

10. Neurologic manifestations associated with COVID-19: a multicentre registry

Author

Abgrall, Sophie, Alby-Laurent, Fanny, Allou, Thibault, Amevigbe, Joséphine, Amarguellay, Hanifa, Alloussi, Nabil, Baille, Guillaume, Barbaz, Mathilde, Bekri, Imen, Bencherif, Lamia, Bensaadi, Samia, Beraud, Guillaume, Bizot, Alexandra, Bottin, Laure, Bruneel, Fabrice, Camdessanche, Jean-Philippe, Chauffier, Jeanne, Csajaghy, Jean-Philippe, De Broucker, Chloé, De Broucker, Thomas, Defebvre, Luc, Delorme, Cécile, Dembloque, Elodie, Derache, Nathalie, Dereeper, Olivier, Derollez, Céline, Descotes-Genon, Cécile, Desestret, Virginie, Devaux, Mathilde, Dubuc, Lydie, Edan, Gilles, Fickl, Andréa, Fraisse, Thibault, Gugenheim, Michel, Hankiewicz, Karolina, Hansmann, Yves, Hautecloque-Raysz, Geoffroy, Henry, Carole, Jobard, Stéphanie, Jouan, Fanny, Kwiatkowski, Arnaud, Lalu, Thibault, Landre, Sophie, Lannuzel, Annie, Leguilloux, Johan, Lejeune, Camille, Liegeois, Clémence, Mahy, Sophie, Marey, Jonathan, Maury, Alexandra, Meppiel, Elodie, Michel, Laure, Mitri, Rita, Moulin, Chloé, Moulin, Solène, Peiffer-Smadja, Nathan, Omarjee, Asma, Ozsancak, Canan, Perrin, Peggy, Petitgas, Paul, Pico, Fernando, Poupard, Marie, Rabier, Valérie, Rizzato, Camille, Roos, Caroline, Saison, Julien, Sayre, Naomi, Sedillot, Nicolas, Sellal, François, Servan, Jérôme, Storey, Caroline, Suchet, Laurent, Tarteret, Paul, Tattevin, Pierre, Thiebaut, Mathilde, Vaduva, Claudia, Varlan, David, Wang, Adrien, Zarrouk, Virginie, Gorza, Lucas, SellaI, François, and de Broucker, Thomas

Published
2021
Full Text
View/download PDF

12. Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins

Author

Kouton, Ludivine, Boucraut, José, Devaux, Jérome, Rajabally, Yusuf A., Adams, David, Antoine, Jean Christophe, Bourdain, Frédéric, Brodovitch, Alexandre, Camdessanché, Jean-Philippe, Cauquil, Cécile, Ciron, Jonathan, Dubard, Thierry, Echaniz-Laguna, Andoni, Grapperon, Aude-Marie, Juntas-Morales, Raul, Kremer, Laurent, Kuntzer, Thierry, Labeyrie, Céline, Lanfranco, Luca, Léger, Jean-Marc, Maisonobe, Thierry, Mavroudakis, Nicolas, Mecharles-Darrigol, Sylvie, Merle, Philippe, Noury, Jean-Baptiste, Rouaud, Violaine, Tard, Céline, Théaudin, Marie, Vallat, Jean-Michel, Viala, Karine, Attarian, Shahram, and Delmont, Emilien

Published
2020
Full Text
View/download PDF

15. Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera

Author

Delmont, Emilien, Brodovitch, Alexandre, Kouton, Ludivine, Allou, Thibaut, Beltran, Stéphane, Brisset, Marion, Camdessanché, Jean Philippe, Cauquil, Cécile, Cirion, Jonathan, Dubard, Thierry, Echaniz-Laguna, Andoni, Grapperon, Aude-Marie, Jauffret, Joëlle, Juntas-Morales, Raul, Kremer, Laurent Daniel, Kuntzer, Thierry, Labeyrie, Céline, Lanfranco, Lucas, Maisonobe, Thierry, Mavroudakis, Nicolas, Mecharles-Darrigol, Sylvie, Nicolas, Guillaume, Noury, Jean-Baptiste, Perie, Maud, Rajabally, Yusuf A., Remiche, Gauthier, Rouaud, Violaine, Tard, Céline, Salort-Campana, Emmanuelle, Verschueren, Annie, Viala, Karine, Wang, Adrien, Attarian, Shahram, and Boucraut, José

Published
2020
Full Text
View/download PDF

16. A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases

Author

Pisella, Lucie Isoline, Fernandes, Sara, Solé, Guilhem, Stojkovic, Tanya, Tard, Céline, Chanson, Jean-Baptiste, Bouhour, Françoise, Salort-Campana, Emmanuelle, Beaudonnet, Guillemette, Debergé, Louise, Duval, Fanny, Grapperon, Aude-Marie, Masingue, Marion, Nadaj-Pakleza, Aleksandra, Péréon, Yann, Audic, Frédérique, Behin, Anthony, Friedman, Diane, Magot, Armelle, Noury, Jean-Baptiste, Souvannanorath, Sarah, Wahbi, Karim, Antoine, Jean-Christophe, Bigaut, Kévin, Camdessanché, Jean-Philippe, Cintas, Pascal, Debs, Rabab, Espil-Taris, Caroline, Kremer, Laurent, Kuntzer, Thierry, Laforêt, Pascal, Laugel, Vincent, Mallaret, Martial, Michaud, Maud, Nollet, Sylvain, Svahn, Juliette, Vicart, Savine, Villar-Quiles, Rocio Nur, Desguerre, Isabelle, Adams, David, Segovia-Kueny, Sandrine, Merret, Géraldine, Hammouda, Elhadi, Molon, Annamaria, and Attarian, Shahram

Published
2021
Full Text
View/download PDF

18. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Kerbrat, Anne, Le Page, Emmanuelle, Bigaut, Kevin, Mathey, Guillaume, Michel, Laure, Ciron, Jonathan, Ruet, Aurelie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al-Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanché, Jean-Philippe, Doghri, Inès, Moulin, Solène, Ben-Nasr, Haifa, Labeyrie, Céline, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Manchon, Eric, Lapergue, Bertrand, Wiertlewski, Sandrine, De Sèze, Jérôme, Vukusic, Sandra, and Laplaud, David Axel

Abstract

IMPORTANCE: Understanding the association between clinically defined relapses and radiological activity in multiple sclerosis (MS) is essential for patient treatment and therapeutic development. OBJECTIVE: To investigate clinical events identified as relapses but not associated with new T2 lesions or gadolinium-enhanced T1 lesions on brain and spinal cord magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: This multicenter observational cohort study was conducted between January 2015 and June 2023. Data were extracted on June 8, 2023, from the French MS registry. All clinical events reported as relapses in patients with relapsing-remitting MS were included if brain and spinal cord MRI was performed within 12 and 24 months before the event, respectively, and 50 days thereafter with gadolinium injection. EXPOSURES: Events were classified as relapses with active MRI (RAM) if a new T2 lesion or gadolinium-enhanced T1 lesion appeared on brain or spinal cord MRI or as acute clinical events with stable MRI (ACES) otherwise. MAIN OUTCOMES AND MEASURES: Factors associated with ACES were investigated; patients with ACES and RAM were compared regarding Expanded Disability Status Scale (EDSS) course, relapse rate, confirmed disability accrual (CDA), relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and transition to secondary progressive (SP) MS, and ACES and RAM rates under each disease-modifying therapy (DMT) were estimated. RESULTS: Among 31 885 clinical events, 637 in 608 patients (493 [77.4%] female; mean [SD] age, 35.8 [10.7] years) were included. ACES accounted for 166 (26.1%) events and were more likely in patients receiving highly effective DMTs, those with longer disease duration (odds ratio [OR], 1.04; 95% CI, 1.01-1.07), or those presenting with fatigue (OR, 2.14; 95% CI, 1.15-3.96). ACES were associated with significant EDSS score increases, lower than those found for RAM. Before the index event, patients with ACES experienced significantly higher rates of relapse (relative rate [RR], 1.21; 95% CI, 1.01-1.46), CDA (hazard ratio [HR], 1.54; 95% CI, 1.13-2.11), and RAW (HR, 1.72; 95% CI, 1.20-2.45). Patients with ACES were at significantly greater risk of SP transition (HR, 2.58; 95% CI, 1.02-6.51). Although RAM rate decreased with DMTs according to their expected efficacy, ACES rate was stable across DMTs. CONCLUSIONS AND RELEVANCE: The findings in this study introduce the concept of ACES in MS, which accounted for one-fourth of clinical events identified as relapses.

Published
2024
Full Text
View/download PDF

19. Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.

Author

Fargeot, Guillaume, Echaniz-Laguna, Andoni, Labeyrie, Céline, Svahn, Juliette, Camdessanché, Jean-Philippe, Cintas, Pascal, Chanson, Jean-Baptiste, Esselin, Florence, Piedvache, Céline, Verstuyft, Céline, Genestet, Steeve, Lagrange, Emmeline, Magy, Laurent, Péréon, Yann, Sacconi, Sabrina, Signate, Aissatou, Nadaj-Pakleza, Aleksandra, Taithe, Frédéric, Viala, Karine, and Tard, Céline

Subjects
OLDER patients, CARDIAC amyloidosis, POLYNEUROPATHIES, TRANSTHYRETIN, NERVE conduction studies, AMYLOIDOSIS
Abstract

Hereditary transthyretin amyloidosis (ATTRv) is an adult-onset autosomal dominant disease resulting from TTR gene pathogenic variants. ATTRv often presents as a progressive polyneuropathy, and effective ATTRv treatments are available. In this 5 year-long (2017–2021) nationwide prospective study, we systematically analysed the TTR gene in French patients with age >50 years with a progressive idiopathic polyneuropathy. 553 patients (70% males) with a mean age of 70 years were included. A TTR gene pathogenic variant was found in 15 patients (2.7%), including the Val30Met TTR variation in 10 cases. In comparison with patients with no TTR gene pathogenic variants (n = 538), patients with TTR pathogenic variants more often presented with orthostatic hypotension (53 vs. 21%, p =.007), significant weight loss (33 vs 11%, p =.024) and rapidly deteriorating nerve conduction studies (26 vs. 8%, p =.03). ATTRv diagnosis led to amyloid cardiomyopathy diagnosis in 11 cases, ATTRv specific treatment in all cases and identification of 15 additional ATTRv cases among relatives. In this nationwide prospective study, we found ATTRv in 2.7% of patients with age >50 years with a progressive polyneuropathy. These results are highly important for the early identification of patients in need of disease-modifying treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases

Author

Do, Le-Duy, Moritz, Christian P., Muñiz-Castrillo, Sergio, Pinto, Anne-Laurie, Tholance, Yannick, Brugiere, Sabine, Couté, Yohann, Stoevesandt, Oda, Taussig, Michael J., Rogemond, Véronique, Vogrig, Alberto, Joubert, Bastien, Ferraud, Karine, Camdessanché, Jean-Philippe, Antoine, Jean-Christophe, and Honnorat, Jérôme

Published
2021
Full Text
View/download PDF

23. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

Author

Jouvenot, Guillaume, Courbon, Guilhem, Lefort, Mathilde, Rollot, Fabien, Casey, Romain, Le Page, Emmanuelle, Michel, Laure, Edan, Gilles, de Seze, Jérome, Kremer, Laurent, Bigaut, Kevin, Vukusic, Sandra, Mathey, Guillaume, Ciron, Jonathan, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Laplaud, David Axel, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al-Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanché, Jean-Philippe, Doghri, Ines, Moulin, Solène, Ben-Nasr, Haifa, Labeyrie, Céline, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Collongues, Nicolas, and Kerbrat, Anne

Abstract

IMPORTANCE: A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity. OBJECTIVE: To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET. DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 patients in the database, data were extracted for 1857 patients 50 years and older with relapsing-remitting MS treated by HET and with no relapse or magnetic resonance imaging activity for at least 2 years. After verification of the medical records, 1620 patients were classified as having discontinued HET or having remained taking treatment and were matched 1:1 using a dynamic propensity score (including age, sex, disease phenotype, disability, treatment of interest, and time since last inflammatory activity). Patients were included from February 2008 to November 2021, with a mean (SD) follow-up of 5.1 (2.9) years. Data were extracted in June 2022. EXPOSURES: Natalizumab, fingolimod, rituximab, and ocrelizumab. MAIN OUTCOMES AND MEASURES: Time to first relapse. RESULTS: Of 1620 included patients, 1175 (72.5%) were female, and the mean (SD) age was 54.7 (4.8) years. Among the 1452 in the HET continuation group and 168 in the HET discontinuation group, 154 patients in each group were matched using propensity scores (mean [SD] age, 57.7 [5.5] years; mean [SD] delay since the last inflammatory activity, 5.6 [3.8] years; mean [SD] follow-up duration after propensity score matching, 2.5 [2.1] years). Time to first relapse was significantly reduced in the HET discontinuation group compared with the HET continuation group (hazard ratio, 4.1; 95% CI, 2.0-8.5; P < .001) but differed between HETs, with a hazard ratio of 7.2 (95% CI, 2.1-24.5; P = .001) for natalizumab, 4.5 (95% CI, 1.3-15.5; P = .02) for fingolimod, and 1.1 (95% CI, 0.3-4.8; P = .85) for anti-CD20 therapy. CONCLUSION AND RELEVANCE: As in younger patients, in patients 50 years and older with nonactive MS, the risk of relapse increased significantly after stopping HETs that impact immune cell trafficking (natalizumab and fingolimod). There was no significant increase in risk after stopping HETs that deplete B-cells (anti-CD20 therapy). This result may inform decisions about stopping HETs in clinical practice.

Published
2024
Full Text
View/download PDF

25. Anti-AGO1 Antibodies Identify a Subset of Autoimmune Sensory Neuronopathy

Author

Moritz, Christian P., primary, Tholance, Yannick, additional, Vallayer, Pierre-Baptiste, additional, Do, Le-Duy, additional, Muñiz-Castrillo, Sergio, additional, Rogemond, Veronique, additional, Ferraud, Karine, additional, La Marca, Coralie, additional, Honnorat, Jerome, additional, Killian, Martin, additional, Paul, Stéphane, additional, Camdessanché, Jean-Philippe, additional, and Antoine, Jean-Christophe G., additional

Published
2023
Full Text
View/download PDF

28. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

Author

Laplaud, David-Axel, Casey, Romain, Barbin, Laetitia, Debouverie, Marc, De Sèze, Jérôme, Brassat, David, Wiertlewski, Sandrine, Brochet, Bruno, Pelletier, Jean, Vermersch, Patrick, Edan, Gilles, Lebrun-Frenay, Christine, Clavelou, Pierre, Thouvenot, Eric, Camdessanché, Jean-Philippe, Tourbah, Ayman, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Lubetzki, Catherine, Papeix, Caroline, Berger, Eric, Heinzlef, Olivier, Debroucker, Thomas, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Magy, Laurent, Defer, Gilles, Guennoc, Anne-Marie, Maubeuge, Nicolas, Labeyrie, Céline, Patry, Ivania, Nifle, Chantal, Casez, Olivier, Michel, Laure, Rollot, Fabien, Leray, Emmanuelle, Vukusic, Sandra, Foucher, Yohann, Fontaine, B., Marignier, R., Durand-Dubief, F., Mathey, G., Le Page, E., Peaureaux-Averseng, D., Ouallet, J.C., Ruet, A., Collongues, N., Hautecoeur, P., Zephir, H., Maillard, E., Cohen, M., Derache, N., Branger, P., Ayrignac, X., Carra-Dalliere, C., Fromont, A., Chamard-Witkowski, L., Taithe, F., Moisset, X., Audoin, B., Rico-Lamy, A., Castelnovo, G., Giannesini, C., Fagniez, O., Bensa, C., Gueguen, A., Kasonde, I. Tabellah, De Vilmarest, A., Montcuquet, A., Vaillants, M., Beltran, S., Creange, A., Ayache, S., Abdellaoui, M., Pottier, C., Slesari, I., Deburghraeve, V., Neau, J.P., Servan, J., Pico, F., Henry, C., and Hankiewicz, K.

Published
2019
Full Text
View/download PDF

30. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: a retrospective observational cohort study

Author

Wilson, Sarah, primary, Calocer, Floriane, additional, Rollot, Fabien, additional, Fauvernier, Mathieu, additional, Remontet, Laurent, additional, Tron, Laure, additional, Vukusic, Sandra, additional, Le Page, Emmanuelle, additional, Debouverie, Marc, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, De Sèze, Jérôme, additional, Zephir, Hélène, additional, Moreau, Thibault, additional, Lebrun-Frénay, Christine, additional, Laplaud, David-Axel, additional, Clavelou, Pierre, additional, Labauge, Pierre, additional, Berger, Eric, additional, Pelletier, Jean, additional, Heinzlef, Olivier, additional, Thouvenot, Eric, additional, Camdessanché, Jean Philippe, additional, Leray, Emmanuelle, additional, Dejardin, Olivier, additional, and Defer, Gilles, additional

Published
2023
Full Text
View/download PDF

31. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Author

Sabathé, Camille, primary, Casey, Romain, additional, Vukusic, Sandra, additional, Leray, Emmanuelle, additional, Mathey, Guillaume, additional, De Sèze, Jérôme, additional, Ciron, Jonathan, additional, Wiertlewski, Sandrine, additional, Ruet, Aurélie, additional, Pelletier, Jean, additional, Zéphir, Hélène, additional, Michel, Laure, additional, Lebrun-Frenay, Christine, additional, Moisset, Xavier, additional, Thouvenot, Eric, additional, Camdessanché, Jean-Philippe, additional, Bakchine, Serge, additional, Stankoff, Bruno, additional, Al Khedr, Abdullatif, additional, Cabre, Philippe, additional, Maillart, Elisabeth, additional, Berger, Eric, additional, Heinzlef, Olivier, additional, Hankiewicz, Karolina, additional, Moreau, Thibault, additional, Gout, Olivier, additional, Bourre, Bertrand, additional, Wahab, Abir, additional, Labauge, Pierre, additional, Montcuquet, Alexis, additional, Defer, Gilles, additional, Maurousset, Aude, additional, Maubeuge, Nicolas, additional, Dimitri Boulos, Dalia, additional, Ben Nasr, Haïfa, additional, Nifle, Chantal, additional, Casez, Olivier, additional, Laplaud, David-Axel, additional, and Foucher, Yohann, additional

Published
2022
Full Text
View/download PDF

33. Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies

Author

Moritz, Christian P., primary, Do, Le-Duy, additional, Tholance, Yannick, additional, Vallayer, Pierre-Baptiste, additional, Rogemond, Véronique, additional, Joubert, Bastien, additional, Ferraud, Karine, additional, La Marca, Coralie, additional, Camdessanché, Jean-Philippe, additional, Honnorat, Jérôme, additional, and Antoine, Jean-Christophe, additional

Published
2022
Full Text
View/download PDF

38. sj-docx-1-msj-10.1177_13524585221139156 – Supplemental material for Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Author

Sabathé, Camille, Casey, Romain, Vukusic, Sandra, Leray, Emmanuelle, Mathey, Guillaume, De Sèze, Jérôme, Ciron, Jonathan, Wiertlewski, Sandrine, Ruet, Aurélie, Pelletier, Jean, Zéphir, Hélène, Michel, Laure, Lebrun-Frenay, Christine, Moisset, Xavier, Thouvenot, Eric, Camdessanché, Jean-Philippe, Bakchine, Serge, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Maillart, Elisabeth, Berger, Eric, Heinzlef, Olivier, Hankiewicz, Karolina, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Montcuquet, Alexis, Defer, Gilles, Maurousset, Aude, Maubeuge, Nicolas, Dimitri Boulos, Dalia, Ben Nasr, Haïfa, Nifle, Chantal, Casez, Olivier, Laplaud, David-Axel, and Foucher, Yohann

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221139156 for Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system by Camille Sabathé, Romain Casey, Sandra Vukusic, Emmanuelle Leray, Guillaume Mathey, Jérôme De Sèze, Jonathan Ciron, Sandrine Wiertlewski, Aurélie Ruet, Jean Pelletier, Hélène Zéphir, Laure Michel, Christine Lebrun-Frenay, Xavier Moisset, Eric Thouvenot, Jean-Philippe Camdessanché, Serge Bakchine, Bruno Stankoff, Abdullatif Al Khedr, Philippe Cabre, Elisabeth Maillart, Eric Berger, Olivier Heinzlef, Karolina Hankiewicz, Thibault Moreau, Olivier Gout, Bertrand Bourre, Abir Wahab, Pierre Labauge, Alexis Montcuquet, Gilles Defer, Aude Maurousset, Nicolas Maubeuge, Dalia Dimitri Boulos, Haïfa Ben Nasr, Chantal Nifle, Olivier Casez, David-Axel Laplaud and Yohann Foucher in Multiple Sclerosis Journal

Published
2022
Full Text
View/download PDF

41. Testing the validity of a set of diagnostic criteria for sensory neuronopathies: a francophone collaborative study

Author

Antoine, Jean-Christophe, Robert-Varvat, Florence, Maisonobe, Thierry, Créange, Alain, Franques, Jérôme, Mathis, Stéphane, Delmont, Emilien, Kuntzer, Thierry, Lefaucheur, Jean-Pascal, Pouget, Jean, Viala, Karine, Desnuelle, Claude, Echaniz-Laguna, Andoni, Rotolo, Francesco, Camdessanché, Jean-Philippe, and The French CIDP study group

Published
2014
Full Text
View/download PDF

42. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.

Author

Sabathé, Camille, Casey, Romain, Vukusic, Sandra, Leray, Emmanuelle, Mathey, Guillaume, De Sèze, Jérôme, Ciron, Jonathan, Wiertlewski, Sandrine, Ruet, Aurélie, Pelletier, Jean, Zéphir, Hélène, Michel, Laure, Lebrun-Frenay, Christine, Moisset, Xavier, Thouvenot, Eric, Camdessanché, Jean-Philippe, Bakchine, Serge, Stankoff, Bruno, Al Khedr, Abdullatif, and Cabre, Philippe

Subjects
MULTIPLE sclerosis, DYNAMICAL systems, CONFIDENCE intervals, DISEASE relapse
Abstract

Background: In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression. Objective: We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy. Methods: Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs). Results: From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09–0.22) for the waiting group and 0.40 (95% CI 0.32–0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30–0.46) and 0.44 (95% CI 0.37–0.52), respectively. Conclusions: By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Interprofessionnalité ville-hôpital autour des patients traités pour un glioblastome.

Author

Assoul, Dalila, Ramirez, Carole, Camdessanché, Jean-Philippe, and Charles, Rodolphe

Subjects
GLIOBLASTOMA multiforme, BRAIN tumors, CAREGIVERS, CENTRAL nervous system tumors, BRAIN
Abstract

Résumé: Les glioblastomes sont des tumeurs cérébrales primitives rares et complexes, tant sur le plan clinique (évolution imprévisible, absence de traitement curatif) que sur le plan humain (accompagnement du patient et de son entourage, gestion de la fin de vie). Ce travail met en lumière les principales difficultés rencontrées par les soignants dans le but de proposer des outils adaptés au sein d'un réseau de soins spécifique. Glioblastomas are rare and complex primary brain tumours, both clinically (unpredictable evolution, lack of curative treatment) and humanly (support for the patient and his or her family, management of the end of life). The aim is to highlight the main difficulties encountered by carers with a view to proposing suitable tools within a specific care network. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Andersen, Johanna B, primary, Sharmin, Sifat, additional, Lefort, Mathilde, additional, Koch-Henriksen, Nils, additional, Sellebjerg, Finn, additional, Sørensen, Per Soelberg, additional, Hilt Christensen, Claudia C, additional, Rasmussen, Peter V, additional, Jensen, Michael B, additional, Frederiksen, Jette L, additional, Bramow, Stephan, additional, Mathiesen, Henrik K, additional, Schreiber, Karen I, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Alroughani, Raed, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Ozakbas, Serkan, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Terzi, Murat, additional, Grammond, Pierre, additional, Grand Maison, Francois, additional, Yamout, Bassem, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Trojano, Maria, additional, McCombe, Pamela, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Turkoglu, Recai, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Granella, Franco, additional, Shaygannejad, Vahid, additional, Prevost, Julie, additional, Skibina, Olga, additional, Solaro, Claudio, additional, Karabudak, Rana, additional, Wijmeersch, Bart V, additional, Csepany, Tunde, additional, Spitaleri, Daniele, additional, Vucic, Steve, additional, Casey, Romain, additional, Debouverie, Marc, additional, Edan, Gilles, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, Sèze, Jérôme D, additional, Maillart, Elisabeth, additional, Zephir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun, Christine, additional, Moreau, Thibault, additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Al-Khedr, Abdullatif, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanché, Jean-Philippe, additional, Marousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Leray, Emmanuelle, additional, Laplaud, David A, additional, Butzkueven, Helmut, additional, Kalincik, Tomas, additional, Vukusic, Sandra, additional, and Magyari, Melinda, additional

Published
2021
Full Text
View/download PDF

49. TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis

Author

Hilezian, Frédéric, primary, Maarouf, Adil, additional, Boutiere, Clemence, additional, Rico, Audrey, additional, Demortiere, Sarah, additional, Kerschen, Philippe, additional, Sene, Thomas, additional, Bensa-Koscher, Caroline, additional, Giannesini, Claire, additional, Capron, Jean, additional, Mekinian, Arsene, additional, Camdessanché, Jean-Philippe, additional, Androdias, Géraldine, additional, Marignier, Romain, additional, Collongues, Nicolas, additional, Casez, Olivier, additional, Coclitu, Catalina, additional, Vaillant, Mathieu, additional, Mathey, Guillaume, additional, Ciron, Jonathan, additional, Pelletier, Jean, additional, and Audoin, Bertrand, additional

Published
2021
Full Text
View/download PDF

50. CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups

Author

Moritz, Christian P., Tholance, Yannick, Stoevesandt, Oda, Ferraud, Karine, Camdessanché, Jean-Philippe, and Antoine, Jean-Christophe

Subjects
Male, Genomics, Middle Aged, Autoantigens, Article, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Case-Control Studies, Humans, Female, Aged, Autoantibodies, Retrospective Studies
Abstract

Objective To discover systemic characteristics in the repertoires of targeted autoantigens in chronic inflammatory demyelinating polyneuropathy (CIDP), we detected the entire autoantigen repertoire of patients and controls and analyzed them systematically. Methods We screened 43 human serum samples, of which 22 were from patients with CIDP, 12 from patients with other neuropathies, and 9 from healthy controls via HuProt Human Proteome microarrays testing about 16,000 distinct human bait proteins. Autoantigen repertoires were analyzed via bioinformatical autoantigenomic approaches: principal component analysis, analysis of the repertoire sizes in disease groups and clinical subgroups, and overrepresentation analyses using Gene Ontology and PantherDB. Results The autoantigen repertoires enabled the identification of a subgroup of 10/22 patients with CIDP with a younger age at onset and a higher frequency of mixed motor and sensory CIDP. IV immunoglobulin therapy responders targeted 3 times more autoantigens than nonresponders. No CIDP-specific autoantibody is present in all patients; however, anchoring junction components were significantly targeted by 86.4% of patients with CIDP. There are potential novel CIDP-specific autoantigens such as the myelination- or axo-glial structure–related proteins actin-related protein 2/3 complex subunit 1B, band 4.1-like protein 2, cadherin-15, cytohesin-1, epidermal growth factor receptor, ezrin, and radixin. Conclusions The repertoire of targeted autoantigens of patients with CIDP differs in a systematic degree from those of controls. Systematic autoantigenomic approaches can help to understand the disease and to discover novel bioinformatical tools and novel autoantigen panels to improve diagnosis, treatment, prognosis, or patient stratification.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results